Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva plus fixed dose-rate gemcitabine for first-line advanced unresectable pancreatic cancer
2006-002742-11Phase 2Completed
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Progression-free survival. Started Jul 2007; status: completed.
02
Drugs
erlotinibgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2006-002742-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002742-11.